ABSTRACT
Congenital hypogonadotropic hypogonadism is defined by reduced steroid hormone synthesis and secretion due to low LH and FSH secretion. It is a rare disease with an unknown prevalence (about 1/5000). It results from a fetal defect in GnRH neuron migration, a defect of pituitary development or from a functional defect of the hypothalamopituitary axis between GnRH neurons and gonadotropic cells. The diagnosis should be considered at birth in males with micropenis, during adolescence in case of delayed puberty or absent puberty, and during adulthood in case of infertility. It may be restricted to the gonadotropic axis, combined with other endocrine system defects or be part of a complex syndrome. Several gene defects have now been described. Molecular studies should be performed to confirm the diagnosis and to help provide appropriate genetic counseling. Treatment to induce puberty should be provided at adolescence, followed by hormonal substitution treatment during adulthood. Specific infertility treatment may also be proposed but patients with the dominant form of gonadotropic deficiency should be informed of the risk of transmission.
Subject(s)
Hypogonadism/physiopathology , Diagnosis, Differential , Female , Follicle Stimulating Hormone/metabolism , Humans , Hypogonadism/diagnosis , Hypogonadism/epidemiology , Hypogonadism/genetics , Incidence , Infant, Newborn , Luteinizing Hormone/metabolism , Magnetic Resonance Imaging , Male , Mutation , SyndromeABSTRACT
Mutations in the MECP2 (Methyl-CpG-binding protein) gene have been reported to cause Rett syndrome (RTT), an X-linked progressive encephalopathy. Recent studies have identified large gene rearrangements that escape the common PCR-based mutation screening strategy and mutations in a novel MeCP2 isoform (named MECP2B). We have collected the results of MECP2 mutational analysis concerning 424 RTT patients conducted in eight laboratories in France. In total, 121 different MECP2 mutations were identified. R168X (11.5%) is the most common of MECP2 mutations, followed by R270X (9%), R255X (8.7%), T158 M (8.3%) and R306C (6.8%). Only eight mutations had relative frequency>3%. Large and complex rearrangements not previously detected using only a PCR-based strategy represent 5.8% of MECP2 mutations. On the contrary, mutation in exon 1 appears to be rare (less than 0.5%). These data demonstrate the high allelic heterogeneity of RTT in France and suggest that routine mutation screening in MECP2 should include quantitative analysis of the MECP2 gene. This study represents an important instrument for molecular diagnosis strategy and genetic counseling in RTT families.
Subject(s)
Methyl-CpG-Binding Protein 2/genetics , Mutation , Rett Syndrome/genetics , Cohort Studies , DNA Mutational Analysis , Exons , Female , Genetic Heterogeneity , HumansABSTRACT
Detailed endocrinological studies were performed in the three affected kindred of a family carrying mutations of the GnRH receptor gene. All three were compound heterozygotes carrying on one allele the Arg262Gln mutation and on the other allele two mutations (Gln106Arg and Ser217Arg). When expressed in heterologous cells, both Gln106Arg and Ser217Arg mutations altered hormone binding, whereas the Arg262Gln mutation altered activation of phospholipase C. The propositus, a 30-yr-old man, displayed complete idiopathic hypogonadotropic hypogonadism with extremely low plasma levels of gonadotropins, absence of pulsatility of endogenous LH and alpha-subunit, absence of response to GnRH and GnRH agonist (triptorelin), and absence of effect of pulsatile administration of GnRH. The two sisters, 24 and 18 yr old, of the propositus displayed, on the contrary, only partial idiopathic hypogonadotropic hypogonadism. They both had primary amenorrhea, and the younger sister displayed retarded bone maturation and uterus development, but both sisters had normal breast development. Gonadotropin concentrations were normal or low, but in both cases were restored to normal levels by a single injection of GnRH. In the two sisters, there were no spontaneous pulses of LH, but pulsatile administration of GnRH provoked a pulsatile secretion of LH in the younger sister. The same mutations of the GnRH receptor gene may thus determine different degrees of alteration of gonadotropin function in affected kindred of the same family.
Subject(s)
Hypogonadism/genetics , Mutation , Receptors, LHRH/genetics , Adult , Base Sequence , DNA/analysis , DNA/chemistry , Follicle Stimulating Hormone/metabolism , Gonadotropin-Releasing Hormone/administration & dosage , Humans , Kinetics , Luteinizing Hormone/metabolism , Male , Pedigree , Periodicity , Sequence AnalysisABSTRACT
Until recently, neonatal hyperthyroidism has been considered to be related to the transplacental passage of thyroid-stimulating Ig present in the serum of the mother. We report here the case of a newborn who presented with severe hyperthyroidism, diffuse goiter, and important ocular signs (eyelid retraction and possibly proptosis). However, the absence of thyroid pathology in the parents and the lack of antithyroid antibodies in the mother and in the patient led us to suspect a nonimmune aetiology. Direct genomic sequencing of the last exon of the TSH receptor in the patient revealed a T-->C transversion yielding to a Met453-->Thr heterozygous substitution in the second transmembrane domain of the receptor. The mutation was absent in both parents. Eukaryotic expression analysis in COS-7 cells yielded a mutated receptor that produced constitutive activation of adenylate cyclase without enhancement of phospholipase C activity.
Subject(s)
Hyperthyroidism/genetics , Mutation , Thyrotropin/genetics , Amino Acid Sequence , Base Sequence , Cell Line/metabolism , Cyclic AMP/metabolism , Humans , Hyperthyroidism/diagnostic imaging , Hyperthyroidism/physiopathology , Infant, Newborn , Male , Molecular Probes/genetics , Molecular Sequence Data , Receptors, Thyrotropin/metabolism , Thyrotropin/pharmacology , Tomography, X-Ray Computed , TransfectionABSTRACT
Familial clustering of Graves' disease indicates a genetic etiology. Searches for genetic factors additional to the known human leukocyte antigen (HLA) association have implicated the gene for the TSH receptor (TSHR). We analyzed the linkage and association among three recently described microsatellite markers within the TSHR introns in Graves' disease in large multiply affected Welsh and English families (223 members, 44 affected individuals). Linkage analysis under a dominant model strongly rejected the hypothesis that TSHR is linked to Graves' disease in these families (lod score = -4.53). More detailed analyses also failed to provide evidence for linkage; these included combined segregation and linkage analysis, correction for HLA-DR3 status, allowance for the levels of thyroid autoantibodies in unaffected pedigree members, consideration of a recessive model for the disease, and linkage disequilibrium between disease and marker alleles. We also considered the possibility of a genetic heterogeneity of Graves' disease and thus analyzed separately the different families with a similar result. Although these results cannot eliminate a minor role of the TSHR gene locus in the genetics of Graves' disease, they argue against it being a major genetic determinant in this pathology.
Subject(s)
Graves Disease/genetics , Receptors, Thyrotropin/genetics , Adolescent , Adult , Female , Genetic Linkage , HLA-DR3 Antigen/genetics , Humans , Lod Score , Male , Middle AgedABSTRACT
We observed four families with loss of function mutations of the TSH receptor gene. One patient had a homozygous Pro162 Ala substitution. The three other were compound heterozygotes: 1) Gln324-->Stop and Asp410 Asn2), Cys41 Ser and Phe525 Leu, 3) Cys390 Trp and Trp546-->Stop. In all patients, the plasma TSH concentration was increased, whereas T3 and T4 concentrations were normal. The TSH levels were normal in the heterozygous parents. These results confirmed the recessive character of TSH receptor defects. Expression of the various mutated receptors in transfected COS-7 cells demonstrated the impairment of their function. We studied the expression of the receptors on the cell surface by immunofluorescence, their ability to bind hormone, and their capacity to activate adenylate cyclase. Some mutations allowed us to identify sites that are especially important for receptor function. The substitution Cys390 Trp abolished high affinity hormone binding. Receptor mutated at Asp410 Asn bound the hormone normally, but failed to activate adenylate cyclase. This result underscores the role of this acidic extracellular residue, close to the first transmembrane segment, in signal transmission. The Phe525 Leu substitution also markedly impaired adenylate cyclase activation, underlining the importance of the second intracellular loop in receptor signaling.
Subject(s)
Mutation , Receptors, Thyrotropin/genetics , Adenylyl Cyclases/metabolism , Adolescent , Adult , Female , Humans , Male , Middle Aged , Receptors, Thyrotropin/analysis , Receptors, Thyrotropin/physiology , Thyrotropin/metabolismABSTRACT
Gonadotropin and GnRH receptors belong to the family of G protein coupled receptors. Gain of function mutations have been described, yielding constitutively active receptors. In the case of the LH receptor these dominant mutations determine familial male limited precocious puberty. Somatic mutations of this receptor may in some cases provoke Leydig-cell adenomas. The constitutive LH receptor is not associated with female precocious puberty. Inactivating mutations are recessive. Alterations in the GnRH receptor determine hypogonadotropic hypogonadism. The clinical diagnosis of this etiology of hypogonadism is extremely difficult, especially in sporadic cases. Mutations of gonadotropin receptors determine primary amenorrhea in girls, whereas in boys they are responsible for Leydig cell aplasia or hypoplasia (LH receptor) or of a variable alteration of spermatogenesis (FSH receptor). Mutations provoking only partial alterations of receptor functions are relatively more frequent, than those inducing complete receptor inactivity. They provide interesting insights into the physiology of GnRH and gonadotropin action.
Subject(s)
Gonadotropins/metabolism , Hypogonadism/physiopathology , Receptors, FSH/metabolism , Receptors, LHRH/metabolism , Receptors, LH/metabolism , Female , Humans , Hypogonadism/genetics , Male , Mutation/genetics , Receptors, FSH/genetics , Receptors, LH/genetics , Receptors, LHRH/geneticsABSTRACT
The thyroid stimulating hormone receptor (TSHR) is the main autoantigen in Graves' disease. Mutations of the TSH receptor have been implicated in various thyroid diseases. In this study, we describe three polymorphic markers localised within introns 2 and 7 of the TSH receptor gene. These markers are useful for the study of genetic diseases involving the TSH receptor. They allowed us to map precisely the TSH receptor gene on chromosome 14q31 between D14S287 and D14S68. We also describe selected primers and experimental conditions for the amplification and direct genomic sequencing of the 10 exons of the receptor gene.
Subject(s)
Chromosomes, Human, Pair 14 , DNA Primers , Microsatellite Repeats , Receptors, Thyrotropin/genetics , Base Sequence , Chromosome Mapping , Exons , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Polymorphism, GeneticABSTRACT
The monoclonal origin of gonadotropin-secreting pituitary adenomas has been well demonstrated but only few molecular abnormalities have so far been recognized in these tumors. For many years, several authors have suggested a role for GnRH and/or GnRH receptors (GnRH-R) in the development of these pituitary adenomas. To test the hypothesis that mutant genes encoding a constitutively activated GnRH-R might be involved in the pathogenesis of these tumors, the sequence of the GnRH-R gene was analyzed in tumoral pituitary tissue obtained from ten patients (six female, four male). The pituitary gonadotropin-secreting adenoma was associated with in vivo hypersecretion of FSH, LH and/or free alpha-subunit (n = 7) or was clinically silent (normal plasma levels of gonadotropins or free alpha-subunit, n = 3). In all cases, immunocytochemical studies of the removed adenoma confirmed their gonadotroph nature by revealing positivity for FSH, LH and/or alpha-subunit. Genomic DNA was extracted from the pathological tissue obtained at neurosurgery. Eight sequencing primers were used to amplify the three exons of the GnRH-R gene from tumoral DNA. The entire coding sequence of the GnRH-R gene was sequenced in the ten adenomas. No mutation was found in any of the tumor specimens examined. In conclusion, mutations in the GnRH receptor coding sequence occur infrequently if at all in gonadotropin-secreting pituitary adenomas.
Subject(s)
Adenoma/genetics , Gonadotropins, Pituitary/metabolism , Mutation , Pituitary Neoplasms/genetics , Receptors, LHRH/genetics , Adenoma/chemistry , Adenoma/metabolism , Adult , Aged , Female , Humans , Immunohistochemistry , Male , Middle Aged , Pituitary Neoplasms/chemistry , Pituitary Neoplasms/metabolism , Sequence Analysis, DNAABSTRACT
The association of hypogonadotropic hypogonadism with anosmia defines Kallmann's syndrome. The gene of the X-linked form of this syndrome has been cloned and several mutations described. However, the relatively small number of hypogonadotropic hypogonadic patients with Kallmann's gene defects supports the hypothesis that other genes may be involved. Idiopathic hypogonadotropic hypogonadism (IHH) is not associated with anosmia. The GnRH gene was excluded as a candidate gene in IHH since no abnormality was found in several patients. The action of the GnRH is mediated through a G-protein coupled receptor present in the cell membrane of gonadotropes. The GnRH receptor was thus another candidate gene. Recently, we described the first patient with partial hypogonadotropic hypogonadism without anosmia caused by loss of function mutations of the GnRH receptor. We compare this first family with a new family presenting complete hypogonadotropic hypogonadism and a variable degree of gonadotrope deficiency in the affected kindred, and discuss genotype-phenotype correlation.
Subject(s)
Hypogonadism/genetics , Mutation/genetics , Receptors, LHRH/genetics , Family Health , Humans , Hypogonadism/complications , Olfaction Disorders/complications , Olfaction Disorders/genetics , Phenotype , Receptors, LHRH/chemistry , Receptors, LHRH/metabolism , Signal Transduction , Structure-Activity RelationshipABSTRACT
Gonadotropin receptors belong to a subgroup of G-protein coupled receptors characterized by a large extracellular domain responsible for the binding of the hormone. Soluble, hormone-binding, alternative splicing variants of the LH receptor, are present in high concentration. A mannose rich precursor form of LH and FSH receptor is accumulated inside target cells. FSH receptors are addressed to the basolateral domain of cells through specific signaling mechanisms. Gonadotropin receptors are also present in endothelial cells of target organ vessels and are involved in hormone transcytosis. Various genetic abnormalities of these receptors (and of the GnRH receptor) are discussed.
Subject(s)
Receptors, FSH , Receptors, LH , Animals , Humans , Receptors, FSH/analysis , Receptors, FSH/chemistry , Receptors, FSH/physiology , Receptors, LH/analysis , Receptors, LH/chemistry , Receptors, LH/physiologyABSTRACT
Some forms of isolated hypogonadotropic hypogonadism are caused by mutations of the GnRH receptor gene. These mutations lead to inactivation of the receptor and are recessive. A unique disease that associates hypogonadotropic hypogonadism and congenital hyperplasia is caused by mutations in the DAX-1 gene, situated on chromosome X. The pathogenesis to these endocrine defects remains now elusive. Kallmann syndrome represents the association of hypogonadotropic hypogonadism due to GnRH deficiency, and anosmia. Additional developmental anomalies can be present. Three modes of inheritance have been described: X-linked, autosomal recessive and autosomal dominant. The X-linked KAL-1 gene has been cloned. It encodes an extracellular matrix protein, anosmin-1, the study of which should lead to a better understanding of this developmental disease.
Subject(s)
Hypogonadism/genetics , Receptors, LHRH/genetics , X Chromosome/genetics , Female , Humans , Hypogonadism/physiopathology , Hypothalamo-Hypophyseal System/pathology , Male , Point Mutation , Receptors, LHRH/physiologyABSTRACT
CONTEXT: Within the last two decades, heterozygous loss-of-function PAX8 mutations have been reported in patients with a wide degree of thyroid gland dysfunction and growth despite the presence of identical mutations. OBJECTIVES: To search for PAX8 mutations in a cohort of patients with congenital hypothyroidism (CH) and various types of thyroid gland defects. DESIGN: A cross-sectional study was conducted in a cohort of patients. SETTING: The French neonatal screening program was used for recruiting patients. PATIENTS: A total of 118 patients with CH, including 45 with familial and 73 with sporadic diseases, were included in this study. The thyroid gland was normal in 23 patients had hypoplasia, 25 had hemithyroid agenesis, 21 had athyreosis, and 21 had ectopy. RESULTS: We found four different PAX8 mutations (p.R31C, p.R31H, p.R108X, and p.I47T) in ten patients (six patients with CH and four family members), two with sporadic and eight with familial diseases. Imaging studies performed in the index cases showed ectopic thyroid gland (n=2), hypoplasia (n=2), eutopic lobar asymmetry (n=1), and eutopic gland compatible with dyshormonogenesis (n=1). The previously reported p.R31C and the novel p.I47T PAX8 mutations are devoid of activity. CONCLUSION: Four different PAX8 mutations were detected in six index patients with CH (ten total subjects). The p.R31C, p.R31H, and p.R108X mutations have been reported. The novel p.I47T PAX8 mutation presented loss of function leading to CH. Thyroid ectopy was observed in two cases of PAX8 (p.R31H) mutation, a finding that has not been reported previously. We observed a high inter-individual and intra-familial variability of the phenotype in PAX8 mutations, underlining that population genetic studies for CH should include patients with various clinical presentations.
Subject(s)
Congenital Hypothyroidism/genetics , Kidney/abnormalities , Mutation , Paired Box Transcription Factors/genetics , Thyroid Dysgenesis/genetics , Thyrotropin/blood , Blotting, Western , Chromatography , Congenital Hypothyroidism/diagnostic imaging , Cross-Sectional Studies , Female , France , Genetic Testing , Humans , Infant, Newborn , Isoleucine , Male , Mutagenesis , Neonatal Screening , PAX8 Transcription Factor , Paired Box Transcription Factors/metabolism , Pedigree , Phenotype , Radionuclide Imaging , Threonine , Thyroid Dysgenesis/diagnostic imaging , Transcriptional Activation , UltrasonographyABSTRACT
GnRH and its receptor GnRHR are key regulators of the hypothalamo-pituitary axis. They modulate the secretion of LH and FSH gonadotropins and therefore, the development and maturation of gonads in fetal life as well as after birth. Congenital functional defect of this axis results in isolated hypogonadotropic hypogonadism (IHH). Several natural mutations causing IHH without anosmia have now been identified in GnRHR or GnRH genes. These mutations inactivate GnRHR or its ligand function and cause highly variable phenotypes, ranging from partial to complete gonadotropic deficiencies. The present review describes the published natural GnRHR mutations and tries to correlate them with the corresponding phenotypes according to the different steps of the GnRH system development.
Subject(s)
Gonadotropin-Releasing Hormone/deficiency , Gonadotropin-Releasing Hormone/genetics , Mutation , Receptors, LHRH/genetics , Animals , Developmental Biology , Humans , Hypogonadism/genetics , PhenotypeSubject(s)
Chromosomal Proteins, Non-Histone , DNA-Binding Proteins/genetics , Repressor Proteins , Rett Syndrome/genetics , Child , Child, Preschool , Cohort Studies , Female , Genetic Testing , Genotype , Humans , Male , Methyl-CpG-Binding Protein 2 , Mutation , Retrospective Studies , Rett Syndrome/diagnosisABSTRACT
Kallmann syndrome (KS) is a heterogeneous genetic disorder that associates variable gonadotropin-releasing hormone (GnRH) deficiency with anosmia and, sometimes, other non-reproductive clinical features. X-linked recessive, as well as autosomal recessive and dominant modes of transmission have been described. The first KS-related gene to be described (KAL1) was in the X-linked form. The second gene (KAL2) was initially unexpected, as it was known to encode the fibroblast growth receptor 1 (FGFR1). Its consideration as a candidate gene arose as a result of cases with contiguous gene syndrome and, initially, mutations were mostly described in familial cases with autosomal dominant transmission of KS. Since its initial discovery, numerous mutations of FGFR1 have been described in several functional domains of the receptor. Genotype-phenotype correlations have shown that some clinical features associated with KS, such as loss of nasal cartilage, hearing impairment, and anomalies of the limbs seem to be mainly associated with KAL2 mutations. The role of FGFR1 in the normal development of the olfactory bulb explains the association of anosmia with GnRH deficiency in FGFR1-mutated patients. Phenotype analysis indicates that FGFR1 is involved in normal migration of GnRH fetal neurons, but this is clearly not the whole story as a substantial proportion of KAL2-mutated individuals have normosmic GnRH deficiency. Finally, recent additional observations, notably using animal models, but also the description of human mutations in a specific ligand of FGFR1, FGF8, are beginning to shed light on the pathogenesis of GnRH deficiency in general, not just KS.
Subject(s)
Kallmann Syndrome/genetics , Neurons/physiology , Receptor, Fibroblast Growth Factor, Type 1/genetics , Animals , Cell Movement/physiology , Female , Gonadotropin-Releasing Hormone , Humans , Hypogonadism/genetics , Hypogonadism/physiopathology , Kallmann Syndrome/physiopathology , Male , Mice , Mutation , Pedigree , Phenotype , Reproduction/geneticsABSTRACT
OBJECTIVE: X chromosome inactivation and the MECP2 genotype do not provide the full explanations for the clinical differences between patients with Rett syndrome (RTT), suggesting the involvement of other factors. One MeCP2 target is the brain-derived neurotrophic factor (BDNF) gene. We investigated, according to the MECP2 genotype, the role of the BDNF functional polymorphism (Val66Met) on the severity of RTT. METHODS: This polymorphism in BDNF was analyzed by PCR and dHPLC in 81 patients with RTT. We studied the association between the MECP2 and BDNF genotypes and the clinical features in each patient. RESULTS: We found that some RTT features can be correlated with MECP2 genotypes. Missense mutations are associated with a more severe epileptic phenotype (early onset and drug resistance) than other mutations. Non-sense and late truncating mutations lead to a less severe phenotype regarding walking. The distribution of the Val66Met polymorphism was not significantly different between the different groups in regard to the severity of all tested symptoms. However, girls with RTT bearing the Val66Val genotype tend to present earlier seizures than girls with RTT bearing the Met66 allele. No girls with RTT with the Met66 allele presented early seizures. CONCLUSIONS: Early onset of seizures is linked to the combined MECP2 and BDNF genotypes. The BDNF Met66 allele may protect against seizures, whereas missense mutations in the MBD of MECP2 are more frequently associated with early seizures.
Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Methionine/genetics , Polymorphism, Genetic/genetics , Rett Syndrome/genetics , Seizures/genetics , Valine/genetics , Adolescent , Adult , Child , Cohort Studies , Female , Humans , Methyl-CpG-Binding Protein 2/genetics , Phenotype , Rett Syndrome/complications , Seizures/etiologyABSTRACT
We describe a familial study of AT III, a type III antithrombin III variant which was identified in the propositus by gene analysis as Pro 41 Leu heterozygous mutation. None of the four members of the family who presented with defective heparin cofactor (hep-cofactor) activity, and therefore probably carried the mutation, had experienced deep venous thrombosis. The abnormal AT III was purified from the propositus' plasma, taking advantage of the difference in NaCl concentrations required to elute variant and normal AT III from heparin-Sepharose. The antithrombin and anti-Xa activities of the purified variant AT III were comparable to those observed for normal AT III, but hep-cofactor activity was strikingly reduced. The enhancement by heparin of thrombin and F Xa inhibition by normal and variant AT III was compared in the absence of NaCl and in the presence of normal NaCl concentrations. The difference between the degrees of inhibition by normal and variant AT III was maximal at physiological ionic strength (i.e. at a concentration of 0.15 M). The quantification of heparin AT III interaction with both normal and variant purified proteins in a double reciprocal plot yielded similar dissociation constants but a 9-fold decrease in the maximal pseudo-first order constant. This suggests that Pro 41 is more involved in the molecular changes induced by heparin than in the primary binding of the activator.
Subject(s)
Antithrombin III/genetics , Dipeptides/genetics , Mutation , Adult , Antithrombin III/isolation & purification , Chemical Phenomena , Chemistry , Chromatography, Affinity , Chromatography, Ion Exchange , Female , Humans , Middle Aged , PedigreeABSTRACT
During differentiation of human promyelocytic HL60 cells into monocytes there are sustained increases in intracellular pH and Na+/H+ antiporter activity. Here we show that increased transcription and expression of the gene for the Na+/H+ antiporter precedes phorbol 12-myristate 13-acetate (PMA)-induced HL60 cell differentiation. PMA increased steady-state Na+/H+ antiporter mRNA levels approximately 50-fold within 8 h (at which time less than 15% of cells had differentiated). This increase was due to an increased transcriptional rate as determined by nuclear run on. Immunoprecipitation of [35S]methionine-labeled Na+/H+ antiporter using an antiporter fusion protein antibody (RP1-c28) showed an equivalent increase in Na+/H+ antiporter protein synthesis. The synthetic diacylglycerol, 1-oleolyl-2-acetylglycerol, an activator of protein kinase C, which unlike PMA did not cause differentiation, failed to induce Na+/H+ antiporter mRNA. Furthermore, inhibition of PMA-induced differentiation by either sphingosine or cycloheximide prevented accumulation of Na+/H+ antiporter mRNA. Together, these findings strongly suggest a close association of Na+/H+ antiporter induction with HL60 cell differentiation. The HL60 cell system is a promising model to study the mechanisms of Na+/H+ antiporter gene regulation and its function in differentiation.
Subject(s)
Carrier Proteins/genetics , Monocytes/physiology , Cell Differentiation/drug effects , Cycloheximide/pharmacology , Diglycerides/pharmacology , Gene Expression/drug effects , Humans , In Vitro Techniques , Leukemia, Myeloid , RNA, Messenger/genetics , Sodium-Hydrogen Exchangers , Sphingosine/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Transcription, Genetic/drug effects , Tumor Cells, CulturedABSTRACT
The vascular smooth muscle cell of the arterial media plays a predominant role in functional and structural alterations of the arterial wall in pathophysiological processes such as arterial hypertension, atheroma, or normal aging. The observed alterations are related to the three activities of the vascular smooth muscle cell, namely contractility, secretion of proteins from the extracellular matrix, and proliferation and migration. In arterial hypertension, vascular smooth muscle cells are functionally more contracted and structurally hypertrophic, and more collagen is secreted than under normal conditions. Similar structural changes are observed in the normal aging process. With respect to vascular smooth muscle cells, atheroma is characterized by their subintimal migration and proliferation, and by excessive excretion of collagen associated with other phenotypic modifications that are expressed in their regression to a myofibroblastic state. Regardless of the pathophysiological context, these phenotypic modifications of the vascular smooth muscle cell are always linked to an activation of the phosphoinositol pathways and to calcium accumulation. The activation of the phosphoinositol pathways seems to be a common feature of the different types of arterial hypertension. This activation can be associated with an increase in vasoactive peptides such as angiotensin II, vasopressin, or endothelin as in the secondary types of hypertension or directly related to an increase in vasoconstriction; or, as an exception, it can be spontaneously active in vivo and in vitro, as in the model of cultured vascular smooth muscle cells of the spontaneously hypertensive rat (SHR).(ABSTRACT TRUNCATED AT 250 WORDS)